Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Melanoma|Merkel Cell Carcinoma, Unspecified|Renal Cell Carcinoma|Non Small Cell Lung Cancer
BIOLOGICAL: zirconium Zr 89 crefmirlimab berdoxam
Best overall response (BOR) assessed by conventional imaging CT and/or MRI using RECIST 1.1 tomography/computed tomography (PET/CT), Best overall response (BOR) assessed by conventional imaging CT and/or MRI using RECIST 1.1 from 3 (or up to 3) consecutive imaging assessments (CT and/or MRI) following onset of immuno-oncology treatment., Baseline to at least 24 or 27 weeks after the start of IOT, depending on treatment schedule.
Largest measured difference from baseline in the lesion major axis from three (or up to three) consecutive standard of care imaging assessments (CT and/or MRI), Largest measured difference from baseline in the lesion major axis from three (or up to three) consecutive standard of care imaging assessments (CT and/or MRI) following onset of immuno-oncology treatment., Baseline to at least 24 or 27 weeks after the start IOT, depending on treatment schedule.|Incidence and severity of AEs, Incidence and severity of AEs, Up to 48 weeks or end of treatment.|Incidence and severity of infusion or injection reactions, Incidence and severity of infusion or injection reactions reported during or shortly after administration of the investigational product., 33 days post infusion|Incidence of withdrawal from scanning protocol due to zirconium Zr 89 crefmirlimab berdoxam related AEs, Incidence of withdrawal from scanning protocol due to zirconium Zr 89 crefmirlimab berdoxam related AEs, Up to 48 weeks or end of treatment|12-lead ECG ventricular rate (bpm), Ventricular rate (bpm) will be recorded from the 12-lead ECG, baseline to 48 weeks or end of study|12-lead ECG PR interval (msec), PR interval (msec) will be recorded from the 12-lead ECG, baseline to 48 weeks or end of study|12-lead ECG QRS interval (msec), QRS interval (msec) will be recorded from the 12-lead ECG, baseline to 48 weeks or end of study|12-lead ECG QT interval (msec), QT interval (msec) will be recorded from the 12-lead ECG, baseline to 48 weeks or end of study|12-lead ECG QTc interval (msec), QTc interval (msec) will be recorded from the 12-lead ECG, baseline to 48 weeks or end of study|12-lead ECG Overall Result, Investigator's overall assessment of the ECG reading will be recorded as normal or abnormal. If abnormal, as either "not clinically significant" or "clinically significant", baseline to 48 weeks or end of study|Anti-drug antibody, Detection of anti-drug antibodies, baseline to 48 weeks or end of study|Change in blood AST levels (U/L) from baseline., Blood AST levels (U/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood ALT levels (U/L) from baseline., Blood ALT levels (U/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood ALP levels (U/L) from baseline., Blood ALP levels (U/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood bilirubin levels (mg/dL) from baseline., Blood bilirubin levels (mg/dL) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood LDH levels (U/L) from baseline., Blood LDH levels (U/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood BUN levels (mg/dL) from baseline., Blood BUN levels (mg/dL) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood GGT levels (U/L) from baseline., Blood GGT levels (U/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in serum creatinine levels (mg/dL) from baseline., Serum creatinine levels (mg/dL) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood uric acid levels (mg/dL) from baseline., Blood uric acid levels (mg/dL) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood sodium levels (mmol/L) from baseline., Blood sodium (mmol/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood potassium levels (mmol/L) from baseline., Blood potassium (mmol/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood chloride levels (mmol/L) from baseline., Blood chloride (mmol/L) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.|Change in blood glucose levels (mg/dL) from baseline., Blood glucose (mg/dL) will be obtained at baseline and collected prior to each administration and 60 minutes post administration., Baseline through 48 weeks or end of treatment.
Evaluate zirconium Zr 89 crefmirlimab berdoxam PET/CT as a discriminator of pseudo-progression., Incidence of iRECIST defined pseudo-progression events., Up to 48 weeks or end of treatment.|Evaluate zirconium Zr 89 crefmirlimab berdoxam PET/CT in subjects who develop clinical and/or radiographic progression to explore mechanisms for treatment resistance., RECIST 1.1 defined Progressive Disease., Up to 48 weeks or end of treatment.|Evaluate zirconium Zr 89 crefmirlimab berdoxam PET/CT as a predictor or surrogate for IOT immune related adverse events (irAEs)., Incidence of Immuno-oncology related TEAEs in non-diseased tissues and organs., Up to 48 weeks or end of treatment.|Correlate zirconium Zr 89 crefmirlimab berdoxam PET uptake with CD8 expression and PD 1/PD-L1 expression as determined by immunohistochemistry (IHC)., CD8 expressing cells and PD-1/PD-L1 expressing cells., Up to 48 weeks or end of treatment.|Evaluate zirconium Zr 89 crefmirlimab berdoxam PET/CT as a predictor of progression free survival (PFS), Patient level Progression Free Survival., Up to 48 weeks or end of treatment.|Evaluate zirconium Zr 89 crefmirlimab berdoxam PET/CT as a predictor of duration of response (DoR)., Patient level Duration of Response., Up to 48 weeks or end of treatment.
The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.